Please use this identifier to cite or link to this item:
|Title:||Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study|
|Citation:||Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study / A. Zurochka, M. Dobrinina, V. Zurochka, et al. — DOI 10.3390/vaccines9060627 // Vaccines. — 2021. — Vol. 9. — Iss. 6. — 627.|
|Abstract:||The present study aimed to assess antibody seropositivity prevalence among symptomatic individuals and individuals with a high risk of occupational exposure to SARS-CoV-2. Participants from Chelyabinsk (Russian Federation) who were at an increased risk of exposure to SARS-CoV-2 (high-risk group, n = 1091) and participants who either had symptoms consistent with COVID-19 or were suspected to have experienced COVID-19 in the past (symptomatic group, n = 692) were enrolled between 28 September and 30 December 2020. Blood samples were tested by enzyme-linked immunosorbent assay D-5501 SARS-Cov-2-IgG-EIA-BEST and D-5502 SARS-Cov-2-IgM-EIA-BEST (AO Vector-Best, Novosibirsk, Russia). The overall seropositivity rate was 28.33–28.53%. SARS-CoV-2 antibodies were detected in 17.23% (adjusted prevalence of 17.17–17.29%) of participants in the high-risk and 45.95% (adjusted prevalence of 45.91–46.24%) in the symptomatic group. Higher IgG and IgM titers were observed in women compared to men, as well as in participants in the symptomatic group compared to those in the high-risk group. The results indicate that the seroprevalence among residents in several Russian regions is low (28.38%) and inadequate to provide herd immunity. The lower seroprevalence among participants in the high-risk group may be attributed to the enforcement of healthcare protocols and the use of adequate personal protective equipment. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.|
|metadata.dc.description.sponsorship:||The reported study was funded by RFBR and NSFC (project No.20-515-55003), by the NSFC (project No. 82161138003), and partly by the Government contract of the Institute of Immunology and Physiology (AAAA-A21-121012090090-9).|
|Appears in Collections:||Научные публикации, проиндексированные в SCOPUS и WoS CC|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.